Companies GRAIL

GRAIL

Sunnyvale

Total Offices: 3

918 Total Employees

Year Founded: 2016

View Website

We're Hiring!

Engineering 3 Finance 1 HR & Recruiting 1 Legal 1

View all jobs

GRAIL Company Growth, Stability & Outlook in Sunnyvale

Updated on September 16, 2026

What's the stability & growth outlook for GRAIL?

The Sunnyvale office is characterized by exposure to a business in a clear growth phase, reinforced by expanding commercial momentum, ecosystem partnerships, and access to capital. Together, these dynamics suggest the Sunnyvale location offers visibility into a scaling company with resources and partnerships that can enable ambitious projects and market expansion.

Key Insight for Candidates

Clear, sustained momentum: post–spin‑off growth in Galleri adoption, payer and EHR integrations, and an active FDA pathway give Sunnyvale teams visible milestones and expanding channels to scale impact—translating into tangible stability and growth opportunities day‑to‑day.

Evidence in Action

Epic EHR Integration — Epic electronic health record integration was announced in April 2026 to streamline Galleri ordering and results across U.S. health systems. Sunnyvale employees benefit from simpler clinical workflows and clearer scaling signals, supporting day-to-day execution and visibility into growth.
PMA And FDA Milestone — A Premarket Approval (PMA) submission in January 2026 and an FDA advisory committee meeting on September 23, 2026 formalize Galleri’s regulatory path. This gives Sunnyvale teams a concrete growth roadmap and aligns cross-functional priorities around evidence and launch readiness.

Positive Themes About GRAIL

Strong Revenue Growth: Recent company disclosures indicate consistent year-over-year increases in total and Galleri revenues alongside rising test volumes through 2025 and the first half of 2026. This pattern signals sustained commercial momentum following the 2024 spin-off.
Strategic Partnerships: Collaborations such as Epic EHR integration, Quest Diagnostics connectivity, and payer/channel wins (including TRICARE and Priority Health) broaden access and distribution for Galleri. These relationships support wider adoption and operational reach.
Investor Backing & Capital Strength: Post–spin-off Nasdaq listing and a $110 million Samsung equity investment, alongside a substantial cash position, provide financial flexibility to fund trials, commercialization, and international expansion. This footing helps underpin ongoing initiatives while regulatory review proceeds.